16 Citazioni (Scopus)

Abstract

Introduction: The discovery of molecular biomarkers and the advent oftargeted therapies have led to a radical change in the treatment of severaltumors, including NSCLC. In the last few years, the number of molecularbiomarkers has rapidly increased, and a growing interest has been recentlyfocused on their potential prognostic and predictive value in clinical settings.Areas covered: This review describes all the molecular biomarkers with prognosticand predictive value in NSCLC, including both clinically approvedbiomarkers, and emerging biomarkers under investigation in clinical trials.Liquid biopsy and applications of circulating biomarkers are also described.Expert opinion: The oncological research is currently focusing on the discoveryand validation of molecular biomarkers in order to promote even morepersonalized treatment strategies. This paradigm of care will expand quicklythanks to the advent of new genotyping technologies, such as nextgenerationsequencing, making it possible to create a molecular-genomicprofile of every patient’s tumor. Liquid biopsy and the use of circulatingbiomarkersrepresent the new challenge of oncological research, with verypromising implications in the management of patients.
Lingua originaleEnglish
pagine (da-a)1553-1566
Numero di pagine14
RivistaExpert Opinion on Biological Therapy
Volume15
Stato di pubblicazionePublished - 2015

Fingerprint

Biomarkers
Biopsy
Therapeutics
Expert Testimony
Liquids
Research
Tumors
Clinical Trials
Technology
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cita questo

@article{7a59d80750954a17a70e7afce68f3fc4,
title = "Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls?",
abstract = "Introduction: The discovery of molecular biomarkers and the advent oftargeted therapies have led to a radical change in the treatment of severaltumors, including NSCLC. In the last few years, the number of molecularbiomarkers has rapidly increased, and a growing interest has been recentlyfocused on their potential prognostic and predictive value in clinical settings.Areas covered: This review describes all the molecular biomarkers with prognosticand predictive value in NSCLC, including both clinically approvedbiomarkers, and emerging biomarkers under investigation in clinical trials.Liquid biopsy and applications of circulating biomarkers are also described.Expert opinion: The oncological research is currently focusing on the discoveryand validation of molecular biomarkers in order to promote even morepersonalized treatment strategies. This paradigm of care will expand quicklythanks to the advent of new genotyping technologies, such as nextgenerationsequencing, making it possible to create a molecular-genomicprofile of every patient’s tumor. Liquid biopsy and the use of circulatingbiomarkersrepresent the new challenge of oncological research, with verypromising implications in the management of patients.",
author = "Francesca Toia and Antonio Russo and Marta Castiglia and Valentina Calo' and Giuseppe Cicero and Daniele Fanale and Francesco Passiglia and Viviana Bazan and Angela Listi' and Giuseppe Bronte and Sergio Rizzo",
year = "2015",
language = "English",
volume = "15",
pages = "1553--1566",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls?

AU - Toia, Francesca

AU - Russo, Antonio

AU - Castiglia, Marta

AU - Calo', Valentina

AU - Cicero, Giuseppe

AU - Fanale, Daniele

AU - Passiglia, Francesco

AU - Bazan, Viviana

AU - Listi', Angela

AU - Bronte, Giuseppe

AU - Rizzo, Sergio

PY - 2015

Y1 - 2015

N2 - Introduction: The discovery of molecular biomarkers and the advent oftargeted therapies have led to a radical change in the treatment of severaltumors, including NSCLC. In the last few years, the number of molecularbiomarkers has rapidly increased, and a growing interest has been recentlyfocused on their potential prognostic and predictive value in clinical settings.Areas covered: This review describes all the molecular biomarkers with prognosticand predictive value in NSCLC, including both clinically approvedbiomarkers, and emerging biomarkers under investigation in clinical trials.Liquid biopsy and applications of circulating biomarkers are also described.Expert opinion: The oncological research is currently focusing on the discoveryand validation of molecular biomarkers in order to promote even morepersonalized treatment strategies. This paradigm of care will expand quicklythanks to the advent of new genotyping technologies, such as nextgenerationsequencing, making it possible to create a molecular-genomicprofile of every patient’s tumor. Liquid biopsy and the use of circulatingbiomarkersrepresent the new challenge of oncological research, with verypromising implications in the management of patients.

AB - Introduction: The discovery of molecular biomarkers and the advent oftargeted therapies have led to a radical change in the treatment of severaltumors, including NSCLC. In the last few years, the number of molecularbiomarkers has rapidly increased, and a growing interest has been recentlyfocused on their potential prognostic and predictive value in clinical settings.Areas covered: This review describes all the molecular biomarkers with prognosticand predictive value in NSCLC, including both clinically approvedbiomarkers, and emerging biomarkers under investigation in clinical trials.Liquid biopsy and applications of circulating biomarkers are also described.Expert opinion: The oncological research is currently focusing on the discoveryand validation of molecular biomarkers in order to promote even morepersonalized treatment strategies. This paradigm of care will expand quicklythanks to the advent of new genotyping technologies, such as nextgenerationsequencing, making it possible to create a molecular-genomicprofile of every patient’s tumor. Liquid biopsy and the use of circulatingbiomarkersrepresent the new challenge of oncological research, with verypromising implications in the management of patients.

UR - http://hdl.handle.net/10447/162659

M3 - Article

VL - 15

SP - 1553

EP - 1566

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

ER -